(The American Conservative)—The Federal Trade Commission needs to keep a watchful eye on Big Pharma’s recent maneuvers to control necessary medicine. Indeed, large pharmaceutical companies are seizing our growing diabetes and obesity crises as an opportunity to cash in on American patients. How? They are attempting to manipulate the production of semaglutide—the primary ingredient in Ozempic and Wegovy—probably because of the undeniable pecuniary success European Big Pharma companies, like Novo Nordisk, are seeing from those sales. Indeed, Ozempic sales in the U.S. were roughly $13.9 billion in 2023. Novo Nordisk itself reported that it experienced an increase of 58 percent in GLP-1 diabetes sales and a 154 percent rise in obesity care sales, largely credited to Ozempic and Wegovy’s distribution.
One primary issue is that the GLP-1 market is almost entirely made up of one of two manufacturers, Lilly and Novo Nordisk. These two companies control almost the total supply of GLP-1 medications. Conservative estimations indicate that Lilly enjoys at least a 56 percent market share in GLP-1 subscriptions. Novo Nordisk makes up the remaining 44 percent.
Given these drugs’ essential role in managing our ongoing diabetes and obesity crises, we can’t be overly reliant on two supply chains, especially when just under half of it is owned by a non-American company, namely Novo Nordisk. When one of these firms makes an economic decision, such as engaging in exclusive dealings or changing prices, it sends a sonic boom throughout the market both for consumers and competitors.
It is why the Trump administration must stay vigilant of Big Pharma’s tactics to harness control over our medicine so that the MAHA agenda can be realized fully.
It is also why Lilly’s recent deals with telemedicine providers is so troubling. On June 10, 2025, high-level officials at Lilly offered remarks at Goldman Sachs’s conference. According to readouts from Lilly’s presentation, the company described the measures it is undertaking to “reduc[e] patient out-of-pocket costs” and how it plans to “enhance[e] direct-to-consumer experiences.”
- Read More: theamericanconservative.com
At Last, a Company With Integrity in the Gold IRA Industry
For several years, I’ve been vetting out precious metals companies in search of the best. I believe in gold and silver but it’s hard to find integrity in the Gold IRA industry. The vast majority operate with shady tactics and gigantic spreads that take advantage of Americans who simply want to protect their life’s savings.
I’ve found a handful that I like and I’ve worked with some of them. By no means would I “unrecommend” them because, again, I vetted them out and found them to be above the fold. Unfortunately, it isn’t hard to be better than the rest when the rest are so darn awful.
After years of searching, I finally found a company that truly operates with integrity. Augusta Precious Metals has three important attributes that set them far above the competition:
- Non-Commissioned Sales Team: I cannot stress how important and unique this is. With just about every other company in the Gold IRA industry, the sales teams make commission from every account they open. This means they steer their clients toward the gold and silver products with the highest commission. With Augusta Precious Metals, the team is solely focused on putting the best gold and silver for their clients into their IRA. They get paid to serve the best interests of the Gold IRA client, NOT their own commission pay.
- Incredibly Low Fees: Most Americans would be shocked if they knew the spread other Gold IRA companies charge. Augusta charges just 5% versus up to 45% elsewhere.
- No Pressure, No Gimmicks: There’s an understanding among most in the Gold IRA industry that fear and pressure is the way to go. Augusta Precious Metals takes a sober approach when working with clients because they hold integrity in the highest possible regard. This is why they don’t offer gimmicks like “free” or “bonus” silver. It’s also why they do not apply pressure tactics to get quick sales. Their educational and transparent approach to doing business is exceedingly rare in the Gold IRA industry.